Literature DB >> 12426773

Osteoprotegerin, RANK, RANKL.

D Stejskal1, J Bartek, R Pastorková, V Růzicka, I Oral, D Horalík.   

Abstract

Osteoprotegerin, RANK (Receptor Activator of Nuclear factor kappa B) and RANKL (Receptor Activator of Nuclear faktor kappa B ligand) became the aim of intensive research. RANK is considered as a hematopoietic surface receptor controlling osteoclastogenesis and calcium metabolism. RANKL may promote osteoresorption by induction of cathepsin K gene expression. The present paper summarizes the most significant data in osteoprotegerin, RANK and RANKL problems obtained.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 12426773     DOI： 10.5507/bp.2001.013

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN： 1213-8118            Impact factor:   1.245


  11 in total

1.  The role of RANK/RANKL/OPG signalling pathways in osteoclastogenesis in odontogenic keratocysts, radicular cysts, and ameloblastomas.

Authors:  Merva Soluk Tekkesin; Sevcihan Mutlu; Vakur Olgac
Journal:  Head Neck Pathol       Date:  2011-06-05

2.  The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.

Authors:  Umit Dundar; Vural Kavuncu; Ihsan H Ciftci; Deniz Evcik; Ozlem Solak; Tuncay Cakir
Journal:  J Bone Miner Metab       Date:  2009-03-20       Impact factor: 2.626

3.  Rank Protein Immunolabeling during Bone-Implant Interface Healing Process.

Authors:  Francisley Avila Souza; Thallita Pereira Queiroz; Eloá Rodrigues Luvizuto; Renato Sussumu Nishioka; Idelmo Rangel Garcia; Paulo Sérgio Perri de Carvalho; Roberta Okamoto
Journal:  Int J Dent       Date:  2010-07-19

4.  Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications.

Authors:  Sarvraj Singh Kohli; Virinder Singh Kohli
Journal:  Indian J Endocrinol Metab       Date:  2011-07

5.  Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin.

Authors:  Alessandra D'Abramo; Claudia D'Agostino; Alessandra Oliva; Marco Iannetta; Gabriella D'Ettorre; Francesco Vullo; Massimo Mancone; Maria Rosa Ciardi; Claudio Maria Mastroianni; Vincenzo Vullo
Journal:  ISRN AIDS       Date:  2013-12-05

6.  Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis.

Authors:  Alessandra D'Abramo; Maria Antonella Zingaropoli; Alessandra Oliva; Claudia D'Agostino; Samir Al Moghazi; Giulia De Luca; Marco Iannetta; Claudio Maria Mastroianni; Vincenzo Vullo
Journal:  Mediators Inflamm       Date:  2014-10-14       Impact factor: 4.711

7.  Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients.

Authors:  Alessandra D'Abramo; Maria Antonella Zingaropoli; Alessandra Oliva; Claudia D'Agostino; Samir Al Moghazi; Giulia De Luca; Marco Iannetta; Gabriella d'Ettorre; Maria Rosa Ciardi; Claudio Maria Mastroianni; Vincenzo Vullo
Journal:  PLoS One       Date:  2016-02-25       Impact factor: 3.240

8.  RANK, RANKL and osteoprotegerin in bone biology and disease.

Authors:  H L Wright; H S McCarthy; J Middleton; M J Marshall
Journal:  Curr Rev Musculoskelet Med       Date:  2009-03-10

9.  Effect of breastfeeding on serum osteoprotegerin and soluble receptor activator of nuclear factor-kappa B ligand in full term neonates.

Authors:  Mandana Rafeey; Amir Ghorbanihaghjo; Fardad Masoumi; Samira Alizadeh; Sina Davari Farid
Journal:  Iran Red Crescent Med J       Date:  2013-10-05       Impact factor: 0.611

10.  Expression and Presence of OPG and RANKL mRNA and Protein in Human Periodontal Ligament with Orthodontic Force.

Authors:  Liliana Otero; Dabeiba Adriana García; Liseth Wilches-Buitrago
Journal:  Gene Regul Syst Bio       Date:  2016-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.